Outcome in 41 patients with late relapse germ cell tumors (GCT) treated with high-dose chemotherapy (HDCT)

被引：0
|
作者：
Lorch, A.
Rick, O.
Hartmann, J. T.
Metzner, B.
Glasmacher, A.
Berdel, W.
Schirren, R.
Bokemeyer, C.
Beyer, J.
机构：
[1] Univ Klinikum Giessen & Marburg, Marburg, Germany
[2] Klin Reinhardshohe, Bad Wildungen, Germany
[3] Univ Klinikum Tuebingen, Tubingen, Germany
[4] Klinikum Oldenburg, Oldenburg, Germany
[5] Univ Klinikum Bonn, Bonn, Germany
[6] Univ Klinikum Muenster, Munster, Germany
[7] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[8] Urban Krankenhaus Berlin, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5086
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The value of high-dose chemotherapy for malignant germ cell tumors
    Oechsle K.
    Honecker F.
    Beyer J.
    Bokemeyer C.
    Der Onkologe, 2007, 13 (5): : 434 - 440
  • [32] The role of high-dose chemotherapy in the management of germ cell tumors
    Bastos, Diogo A.
    Feldman, Darren R.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (03) : 284 - 293
  • [33] The role of high-dose chemotherapy in relapsed germ cell tumors
    Rick, O
    Kollmannsberger, C
    Hartmann, JT
    Braun, T
    Siegert, W
    Bokemeyer, C
    Beyer, J
    WORLD JOURNAL OF UROLOGY, 2004, 22 (01) : 25 - 32
  • [34] Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?
    Darren R Feldman
    Robert J Motzer
    Dean F Bajorin
    Nature Clinical Practice Urology, 2008, 5 : 78 - 79
  • [35] The role of high-dose chemotherapy in relapsed germ cell tumors
    O. Rick
    C. Kollmannsberger
    J. T. Hartmann
    T. Braun
    W. Siegert
    C. Bokemeyer
    J. Beyer
    World Journal of Urology, 2004, 22 : 25 - 32
  • [36] High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors
    Ammakkanavar, Natraj Reddy
    Matei, Daniela
    Abonour, Rafat
    Einhorn, Lawrence H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 226 - U148
  • [37] Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
    Nieto, Yago
    Tannir, Nizar M.
    Tu, Shi-Ming
    Jones, Roy B.
    Zurita, Amado J.
    Aparicio, Ana
    Bassett, Roland
    Margolin, Kim Allyson
    Holmberg, Leona
    Champlin, Richard E.
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Late relapse in chemotherapy-treated germ cell tumour patients
    Gerl, A
    Hentrich, M
    Clemm, C
    Schmeller, N
    Hartenstein, R
    Wilmanns, W
    GERM CELL TUMOURS IV, 1998, : 309 - 314
  • [39] Consolidative high-dose chemotherapy (HDCT) after conventional-dose chemotherapy (CDCT) as first salvage treatment for male patients (pts) with metastatic germ cell tumors (mGCTs).
    Beausoleil, Michel S.
    Potvin, Kylea R.
    Howson-Jan, Kang
    Ernst, D. Scott
    Stitt, Larry
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [40] Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.
    Necchi, Andrea
    Miceli, Rosalba
    Bregni, Marco
    Oechsle, Karin
    Kanfer, Edward
    Massard, Christophe
    Flechon, Aude
    Laszlo, Daniele
    Arpaci, Fikret
    Wuchter, Patrick
    Crysandt, Martina Margrit
    Unal, Ali
    Nagler, Arnon
    Wahlin, Anders
    Michieli, Mariagrazia
    Pflueger, Karl-Heinz
    Ringhoffer, Mark
    Badoglio, Manuela
    Pedrazzoli, Paolo
    Lanza, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345